Celltech may abandon launch of treatment for Crohn's disease
Wednesday 31 July 2002
Celltech shareholders suffered a double blow yesterday when the company said it was considering abandoning the launch of its most advanced new drug and would halve its US salesforce.
The drug, Humicade, was being tested as a treatment for Crohn's disease, which causes inflammation of the gut, and had been expected on the market next year. But clinical trials failed to show it was effective.
The data suggests Humicade could still be useful in the treatment of acute forms of the disease, but Celltech said it would talk to US and European regulators to establish if it was likely to gain approval. Analysts predicted that, if the regulator said it would need additional trials to be carried out, the company would drop the product and concentrate development work on a second drug, CDP 870. This is a more effective product treating the same diseases as Humicade.
The company said it is to set up a specialist gastroenterology salesforce in advance of the launch of CDP 870, and that it had paid $6m to the US giant Pharmacia to license Dipentum, a treatment for an inflammatory bowel disorder which had sales of $11m in 2001.
But it is cutting its losses on Metadate, a once promising treatment for hyperactive children. The disappointing sales mean it can no longer sustain a US salesforce of 350, and this will be slashed to 170. The drug will no longer be actively marketed, and sales are unlikely to grow beyond the current $25m a year.
Metadate has struggled in the cut-throat US market for treating hyperactive children. Johnson & Johnson's Concerta has a 25 per cent market share and Shire Pharmaceuticals, the UK's number three drug company, will say later this week that it has won a 26 per cent share with its product Adderall.
Celltech shares fell more than 7 per cent to 397p.
- 1 Venezuela Expo Tattoo 2015: Extreme body art from 'Vampire Woman' to 109mm earlobes
- 3 Ball pool for adults opens in London
- 4 Game of Thrones season 5 trailer: The first full-length look is here
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Boris Johnson claims porn-obsessed Islamic jihadists are 'literally w*****s'
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Putin opponent reveals Russian President's daughter's secret identity
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
King Abdullah dead: We can't afford not to hold Saudi Arabia's royals to account
iJobs Money & Business
£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...